• Netarsudil and Predictive siRNA Codelivery

  2026-10-14

  Slaughter et al. developed a screening and machine-learning framework for predicting whether ionizable drugs can complex siRNA and function as drug-rich nanoparticle components. Netarsudil was predicted to be a strong candidate and was experimentally associated with CTGF siRNA activity and actin-network remodeling in immortalized human trabecular meshwork cells. The study supports a materials-design hypothesis, but its cellular findings do not by themselves establish therapeutic efficacy, ocular delivery, aqueous humor outflow regulation, or clinical benefit.

• Mithramycin A: Evidence and Applicability Boundaries

  2026-10-14

  Mithramycin A is an anticancer antibiotic with vendor-described G-C-rich DNA-binding and transcriptional effects. The supplied cardiac study instead examines the miR-24-3p/Sp1/PI3K axis in doxorubicin-induced heart-failure models; it does not test mithramycin or establish a cardiac application for the compound.

• CPSIT_0844 and TLR-Linked Inflammation

  2026-10-13

  A source-grounded overview of a 2026 study linking the Chlamydia psittaci protein CPSIT_0844 to IL-6 and IL-8 production in THP-1 monocytes through TLR2/TLR4–MyD88, MAPK and NF-κB-associated signaling.

• Astrocyte Heterogeneity Across Brain Space and Time

  2026-10-13

  A source-grounded overview of Schroeder et al.’s mouse–marmoset astrocyte atlas, emphasizing its research question, cross-species conceptual design, reported transcriptomic and morphological findings, and the limits of inferring function from atlas-level data.

• Q-VD-OPh: Identity and Evidence Boundaries

  2026-10-12

  Q-VD-OPh is identified by APExBIO as a pan-caspase inhibitor intended for apoptosis-related research. The supplied product information supports describing its proposed conceptual scope, but no matched peer-reviewed paper was provided, so claims about potency, permeability, disease models, cryopreservation, or biological outcomes remain supplier-reported and cannot be independently assessed here.

• Laminin (925-933) in ECM and Islet Organoids

  2026-10-12

  The supplied evidence connects laminin-related extracellular-matrix biology with islet-organoid research, but it does not establish that Laminin (925-933) was tested in the collagen-VI-enriched scaffolds reported by Zhu et al. The peptide’s documented activity comes from supplier-described cell-adhesion and chemotaxis models, whereas the organoid study evaluated decellularized amniotic-membrane and collagen-VI-based matrices in iPSC-derived islet organoids and diabetic mice. These findings are therefore conceptually related but not directly interchangeable.

• Caspase-3 Activity: Evidence and Boundaries

  2026-10-11

  A source-grounded overview of what DEVD-dependent fluorometric caspase activity measurement can show, how it relates to recent findings on RSL3-driven ferroptosis–apoptosis crosstalk, and where interpretation must remain cautious.

• DeferoxamineB in Ferroptosis Translation

  2026-10-10

  DeferoxamineB offers a mechanistic lens for separating iron-dependent stress from copper-driven cell death. This thought-leadership analysis connects its chelation biology with a 2024 Chemical Engineering Journal study while emphasizing evidence boundaries, translational questions, and why it should be treated as a hypothesis-generating cancer research compound rather than a universal ferroptosis enhancer.

• Q-VD-OPh: Five Questions for Better Evidence

  2026-10-09

  A source-grounded overview of Q-VD-OPh as a pan-caspase inhibitor, emphasizing mechanism, evidence quality, interpretation, applicability and limitations rather than experimental instructions.

• Biomimetic Chromatography for Lung Permeability

  2026-10-09

  A 2024 Journal of Chromatography A study compared immobilised artificial membrane liquid chromatography with liposome electrokinetic capillary chromatography for modeling drug–membrane partitioning and pulmonary permeability. The findings indicate that LEKC can better reflect apparent lung permeability for many compounds, whereas IAM LC offers broader compound coverage and more straightforward high-throughput use.

• MK0787 vs Cefoperazone: 1982 β-Lactam Evidence

  2026-10-08

  Cullmann and colleagues compared N-formimidoyl thienamycin (MK0787) with several newer β-lactams across resistant clinical isolates, highlighting especially strong activity against Pseudomonas aeruginosa and Acinetobacter spp. The study also showed that MK0787 was bactericidal against the tested gram-negative isolates and that its activity was not obviously reduced by β-lactamase production, while cefoperazone served as an important comparator rather than the principal innovation.

• Keap1–Nrf2 Inhibition and Neuronal Ferroptosis in AD

  2026-10-08

  The reference study identifies compound 4–95 as a selective Keap1–Nrf2 protein–protein interaction inhibitor that suppresses ferroptosis-related neuronal injury in cellular and mouse models of Alzheimer’s disease. Its main contribution is linking Nrf2 activation, GPX4/SLC7A11 preservation, reduced amyloid and Tau pathology, and improved cognitive performance within one preclinical framework.

• How HIV-1 Remodels Nuclear Pores in Resting T Cells

  2026-10-07

  Mesner and colleagues show that HIV-1 cell–cell spread can make resting CD4+ T cells permissive by activating CD4–LCK–CDK1 signalling and remodeling nuclear pore complexes. The study shifts attention from viral dose alone to contact-dependent control of capsid nuclear import, while also defining important limits on how in vitro findings should be applied to infection in vivo.

• LDN-193189 in BMP and Corneal Epithelial Research

  2026-10-07

  LDN-193189 is an ALK inhibitor used as a research tool to examine BMP signaling, but the strongest supplied evidence concerns its inclusion in a six-component culture system rather than isolated drug activity. This overview compares the supplier’s mechanistic claims with findings from a peer-reviewed mouse corneal epithelial study and defines the limits of translation.

• 3-Deazaadenosine: Methylation Research Context

  2026-10-06

  3-Deazaadenosine is a supplier-described S-adenosylhomocysteine hydrolase inhibitor used to study methylation-dependent biology and preclinical antiviral research. This overview separates that biochemical rationale from findings in a 2024 ulcerative colitis study of METTL14, highlighting what the evidence supports, where comparisons are only conceptual, and why the reported pathway cannot be treated as proof of 3-Deazaadenosine activity.

8850 records 1/590 page Next 12345 下5页 Last page